TWIST Session 10:

Preventing harms and problems from substance use

8

(This session will be repeated to allow more participation)

Tuesday 24th October, 16:30h – 18:00h (Room 1.08) & Wednesday 25th, 12:45h – 14:15h (Room 1.07)



Harry Sumnall, PhD, Professor in Substance Use, Public Health Institute, Liverpool John Moores University, UK.

Harry Sumnall is a Professor in Substance Use at the Public Health Institute. His research focuses on many aspects of substance use, particularly young people's health issues. Harry's funded research programmes have examined the evidence base for substance misuse prevention and the mechanisms for implementing evidence based practice and policy. Between 2008 and 2015 he received EU funding to develop quality standards in drug prevention and has been awarded and participated in many large domestic and international research projects


Harry is a member of the UK Advisory Council on the Misuse of Drugs, a Board Member of the European Society for Prevention Research, and a Trustee of the UK prevention charity Mentor UK. He is an Editorial Board Member of Addictive

Behaviors, and will soon be serving the same role for the International Journal of Drug Policy

Fabrizio Faggiano, PhD, MD, Professor at the School of Medicine of the Avogadro University of the Eastern Piedmont, Novara, Italy.

Fabrizio Faggiano is an epidemiologist and Professor of Public Health. He is the coordinator of EUDAP - European Drug Abuse Prevention trial.

He is a member of the Board of the EUDAP Faculty. Chair of the Regional Monitoring Center for Drug Addiction Epidemiology - Piemonte. Founder of EUSPR - European Society for Prevention Research. Member of the editorial board of the Cochrane Drugs and Alcohol Review Group. Dr Faggiano's work focuses on the evaluation of prevention models and programmes in school and community settings, with specific expertise in substance use, alcohol and tobacco, and a special focus on health inequities and innovative health systems approaches.



Session Description:

Learning objective(s):

- Gain understanding the scope, theory, and main intervention models of contemporary drug prevention, including links to harm reduction and treatment
- Learn about how prevention activities are embedded in wider policy and social environments
- The evidence base for effective prevention, and how prevention activities might be improved through research

Scope/main topics covered:

- Defining prevention activities with reference to the Institute of Medicine Model; its relationship with treatment and harm reduction; expansion into environmental policies
- Overview of relevant behavioural change theories
- Evidence for effective and ineffective approaches; brief reference to health economic studies of prevention
- Discussion of the importance and challenges of taking a multiple risk behaviour perspective of prevention;
- Guidance on additional resources that help students develop and evaluate prevention activities
- The future of prevention in a changing world, e.g. new technologies; drug policy reform; newly emerging drugs (NPS fentanils)

Training/Learning formats:

• Lecture, class discussions, reference to papers in the main Addictions programme



TWIST Session 10: Preventing harms and problems from substance use

Session Description (cont):

Learning outcome(s) (what should the trainee be able to do following the session?):

- Trainees will be able to provide a comprehensive definition of prevention that encompasses a range of activities and incorporates a socioecological understanding of health and wellbeing;
- to discuss the strengths, limitations, and relevance of a preventative approach to drug use in a changing world;
- to identify effective and ineffective prevention approaches, and how research has contributed to this understanding;
- to understand how prevention fits into wider drug policy actions, and the challenges faced in developing and delivering prevention activities

Related LxAddictions 2017 sessions:

PS19 (prevention theory and practice) & SS20 (ESPAD), SS43 (etiology implications), SS39 (evidence), SS40 (UPC), SS41 (registry), & SS37 (Nightlife)